Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of a recombinant chimpanzee adenoviral vector SARS-CoV-2 vaccine in healthy adults
ChiCTR2100049530Phase 2Not yet recruiting
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Aug 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoints: IgG antibody, Neutralizing antibody by pseudovirus neutralization assay and 1 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100049530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049530.